Sean Parker-backed cell therapy startup ArsenalBio plucks Merck VP as new CSO

Merck’s immuno-oncology superstar Nicholas Haining has been appointed CSO at ArsenalBio, which is working on an approach to programmable cell therapies.

The addition of a high-profile appointment like Haining, who co-founded the company but has been serving as VP of discovery oncology and immunology at Merck...

Click to view original post